Skip to main content
. 2020 Jul 22;20:683. doi: 10.1186/s12885-020-07169-6

Fig. 1.

Fig. 1

Rationale for combining chemotherapy, bevazicumab and atezolizumab. DC, dendritic cell; ICD, immunogenic cell death; MDSCs, myeloid-derived suppressor cells; Tregs, regulatory T cells; VEGF: Vascular Endothelial Growth Factor